Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma

References

• BurninghamZ, Mia HashibeLS. The epidemiology of sarcoma. Am J Dis Child. 2012;2:14. doi:10.1186/2045-3329-2-14
   Google Scholar
• ClarkMA, FisherC, JudsonI, ThomasJM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353(7):701–711. doi:10.1056/nejmra04186616107623
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures;2021Am Cancer Soc. 2021:1–70.
   Google Scholar
• StillerCA, BottaL, BrewsterDH, et al. Survival of adults with cancers of bone or soft tissue in Europe—report from the EUROCARE-5 Study. Cancer Epidemiol. 2018;56(August):146–153. doi:10.1016/j.canep.2018.08.01030179828
   PubMed Web of Science ®Google Scholar
• FabianoS, ContieroP, BarigellettiG, et al. Epidemiology of soft tissue sarcoma and bone sarcoma in Italy: analysis of data from 15 population-based cancer registries. Sarcoma. 2020;2020:1–10. doi:10.1155/2020/6142613
   Google Scholar
• WafaAA. Kingdom of Saudi Arabia a Saudi health council national health information center. Saudi cancer registry cancer incidence report Saudi Arabia; 2016. Available from: https://nhic.gov.sa/en/eServices/Documents/2016.pdf.
   Google Scholar
• FletcherCDM, BridgeJA, HogendoornMF. World Health Organization Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC Press; 2013.
   Google Scholar
• GamboaAC, GronchiA, CardonaK. Soft‐tissue sarcoma in adults: an update on the current state of histiotype‐specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70(3):200–229. doi:10.3322/caac.2160532275330
   PubMed Web of Science ®Google Scholar
• KasperB, SleijferS, LitièreS, et al. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol. 2014;25(3):719–724. doi:10.1093/annonc/mdt58624504442
   PubMed Web of Science ®Google Scholar
• SeddonB, StraussSJ, WhelanJ, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled Phase 3 trial. Lancet Oncol. 2017;18(10):1397–1410. doi:10.1016/S1470-2045(17)30622-828882536
   PubMed Web of Science ®Google Scholar
• JudsonI, VerweijJ, GelderblomH, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–423. doi:10.1016/S1470-2045(14)70063-424618336
   PubMed Web of Science ®Google Scholar
• KaravasilisV, SeddonBM, AshleyS, Al-MuderisO, FisherC, JudsonI. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer. 2008;112(7):1585–1591. doi:10.1002/cncr.2333218278813
   PubMed Web of Science ®Google Scholar
• BlayJY, Van GlabbekeM, VerweijJ, et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer. 2003;39(1):64–69. doi:10.1016/S0959-8049(02)00480-X12504660
   PubMed Web of Science ®Google Scholar
• Léon BérardC, van der GraafA, ChawlaSP. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–1886. doi:10.1016/S014022595799
   PubMed Web of Science ®Google Scholar
• SavinaM, Le CesneA, BlayJY, et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC Observational Study. BMC Med. 2017;15(1):1–11. doi:10.1186/s12916-017-0831-728049467
   PubMed Web of Science ®Google Scholar
• KitagawaD, YokotaK, GoudaM, et al. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells. 2013;18(2):110–122. doi:10.1111/gtc.1202223279183
   PubMed Web of Science ®Google Scholar
• NakamuraT, MatsumineA, KawaiA. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) Study. Cancer. 2016;122(9):1408–1416. doi:10.1002/cncr.2996126970174
   PubMed Web of Science ®Google Scholar
• HuangPW, ChouWC, ShenWC, et al. Hand–foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: a multicenter study in the Asian population. Asia Pac J Clin Oncol. 2018;14(4):353–360. doi:10.1111/ajco.1302929900662
   PubMed Web of Science ®Google Scholar
• EisenhauerEA, TherasseP, BogaertsJ, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Martin-LiberalJ, BensonC, McCartyH, ThwayK, MessiouC, JudsonI. Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis. Clin Sarcoma Res. 2013;3(1):1–5. doi:10.1186/2045-3329-3-1323351922
   PubMedGoogle Scholar
• JonesRL, KatzD, LoggersET, DavidsonD, RodlerET, PollackSM. Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma. Med Oncol. 2017;34(10):1–5. doi:10.1007/s12032-017-1030-227889880
   PubMed Web of Science ®Google Scholar
• SzucsZ, MessiouC, WongHH, et al. Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anticancer Drugs. 2017;28(4):421–426. doi:10.1097/CAD.000000000000047428099210
   PubMed Web of Science ®Google Scholar
• ToulmondeM, PulidoM, Ray-CoquardI, et al. Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, Phase 2 Study. Lancet Oncol. 2019;20(9):1263–1272. doi:10.1016/S1470-2045(19)30276-131331699
   PubMed Web of Science ®Google Scholar
• UrakawaH, KawaiA, GotoT, et al. Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: a Japanese Musculoskeletal Oncology Group Study. Cancer Sci. 2020;111(9):3303–3312. doi:10.1111/cas.1454232579783
   PubMed Web of Science ®Google Scholar
• KollárA, JonesRL, StacchiottiS, et al. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol (Madr). 2017;56(1):88–92. doi:10.1080/0284186X.2016.1234068
   PubMed Web of Science ®Google Scholar
• KocaS, BeşiroğluM, ÖzçelikM, et al. Pazopanib for metastatic soft-tissue sarcoma: a multicenter retrospective study. J Oncol Pharm Pract. 2020;27(3):541–6. doi:10.1177/107815522092407532419618
   PubMed Web of Science ®Google Scholar
• KaraağaçM, SezginY, EryılmazMK, ArazM, KaplanMA, ArtaçM. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: a Retrospective Cross-Sectional Study of a Turkish cohort. J Oncol Pharm Pract. 2020;26(7):1657–1666. doi:10.1177/107815522090413832063110
   PubMed Web of Science ®Google Scholar
• ChungOR, HongJY, KimJH, et al. Real-world outcomes of pazopanib treatment in Korean patients with advanced soft tissue sarcoma: a Multicenter Retrospective Cohort Study. Target Oncol. 2020;15(4):485–493. doi:10.1007/s11523-020-00731-z32607656
   PubMed Web of Science ®Google Scholar
• SetoT, SongM-N, TrieuM, et al. Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in Northern California. Med Sci. 2019;7(3):48. doi:10.3390/medsci7030048
   Google Scholar
• VosM, SleijferS, LitièreS, et al. Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials. Acta Oncol (Madr). 2019;58(6):872–879. doi:10.1080/0284186X.2019.1581376
   PubMed Web of Science ®Google Scholar
• BianchiL, RossiL, TomaoF, PapaA, ZorattoF, TomaoS. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma. Endocr Relat Cancer. 2013;20(5):R233–R245. doi:10.1530/ERC-13-020123833016
   PubMed Web of Science ®Google Scholar
• BoL, ZhouL, TangY, LiuY, LiH, Wang K. Tyrosine Kinase Inhibitors–Induced Hypothyroidism as a Prognostic Factor in Metastatic Renal Cell Carcinoma: a Systematic Review and Meta-Analysis. 2020:1–13[Preprint]. Available from: https://www.researchsquare.com/article/rs-36842/v1. doi:10.21203/rs.3.rs-36842/v1
   Google Scholar
• LiuG, Ke LC, Sun SR. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: a meta-analysis. Medicine (Baltimore). 2018;97(36):e121766. doi:10.1097/MD.0000000000012176
   Google Scholar